MedTrace Logo

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

NCT01108783 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2012-04-05

No results posted yet for this study

Summary

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Bilastine

20 mg (encapsulated) tablets QD/14 days

DRUG

Desloratadine

5 mg (encapsulated) tablets QD/14 days

DRUG

Placebo

(encapsulated) Tablets QD/14 days

Sponsors & Collaborators

  • Faes Farma, S.A.

    lead INDUSTRY

Principal Investigators

  • Piotr Kuna, Prof. Dr. · Barlicki University Hospital, Medical University of Lodz (Poland)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2003-08-31
Completion
2004-02-29

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108783 on ClinicalTrials.gov